Semaglutide - Dr. Reddy’s Fully Synthetic Peptide API
Semaglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist, with 94% sequence homology to human GLP-1 indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus.
In this whitepaper, we look at Dr. Reddy’s Semaglutide, a synthetic peptide identical to the innovator molecules. As the innovator molecule and unlike most generic versions in the market, it is neither a base addition salt (Sodium, Potassium, and the likes) nor an acid addition salt (Acetate, Trifluoroacetate, Hydrochloride, and the likes).
Dr. Reddy’s provides a unique end-to-end product offering where customers can choose from the following business models:
- API purchase
- API + device purchase
- Combination of API and Salcaprozpate sodium (SNAC) for oral formulation
- Finished formulations purchase
To know more about our API offerings, please read the White paper on Semaglutide by filling the contact from below.
Explore other Whitepapers:Know More
Please fill the Contact form below in order to view the white paper